On the Couch with Dr Liz Dallimore (Argenica): Phase Two, FDA and What's Ahead
In this episode of On the Couch, Henry Jennings speaks with Dr Liz Dallimore, CEO of Argenica Therapeutics (ASX: AGN). Fresh from presenting phase two trial data at a major international stroke conference, Liz walks through what the results showed, why neuroprotection is such a difficult space, and what the path forward looks like for the company. — Marcus Today – Daily Market Insights Marcus Today provides clear, practical commentary for self-directed investors – covering markets, portfolios...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from On the Couch
On the Couch with Jon Pilcher (Neuren): DAYBUE, Europe and What Comes Next
On the Couch with Nick Griffin (Munro Partners): Markets, AI and Global Tech Themes
Why the Next Six Months Could Get Tough for Small Caps: On the Couch with Chris Stott
On the Couch with Coby Hanoch (Weebit Nano): The Memory Boom Behind AI
Get summaries like this every morning.
Free AI-powered recaps of On the Couch and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.